Celcuity Inc. (CELC)
10.24
0.25 (2.50%)
At close: Apr 17, 2025, 3:59 PM
11.40
11.33%
Pre-market: Apr 21, 2025, 04:30 AM EDT
2.50% (1D)
| Bid | 9.74 |
| Market Cap | 387.48M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -111.78M |
| EPS (ttm) | -2.83 |
| PE Ratio (ttm) | -3.62 |
| Forward PE | -3.35 |
| Analyst | Buy |
| Ask | 11.4 |
| Volume | 163,017 |
| Avg. Volume (20D) | 277,761 |
| Open | 9.94 |
| Previous Close | 9.99 |
| Day's Range | 9.55 - 10.34 |
| 52-Week Range | 7.58 - 19.77 |
| Beta | 0.43 |
About CELC
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 20, 2017
Employees 87
Stock Exchange NASDAQ
Ticker Symbol CELC
Website https://www.celcuity.com
Analyst Forecast
According to 6 analyst ratings, the average rating for CELC stock is "Buy." The 12-month stock price forecast is $27, which is an increase of 163.67% from the latest price.
Stock Forecasts2 weeks ago
-8.11%
Celcuity shares are trading lower after the compan...
Unlock content with
Pro Subscription
5 months ago
-10.28%
Celcuity shares are trading lower after the company reported worse-than-expected Q3 EPS results.
